Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: We compared the efficacy of sub-Tenon triamcinolone acetonide (STTA) to intravitreal triamcinolone aceto-nide (IVTA) injections during cataract surgery (CS) for patients with diabetic macular edema (DME).
Methods: The medical records of 33 eyes (26 patients) with DME which had undergone CS with STTA were compared to those of 34 eyes (27 patients) with DME which had undergone CS with IVTA. Central foveal thickness and best-corrected visual acuity (BCVA) were measured at the baseline and 1, 3, and 6 months after the surgery.
Results: The BCVAs after STTA and IVTA were significantly improved at 3 and 6 months. Thirteen eyes in the IVTA group and 21 eyes in the STTA group required other therapies (p < 0.05). One case developed intraocular pressure elevation after IVTA and underwent selective la ser trabeculoplasty.
Conclusions: Ophthalmologists should consider the merits and demerits of IVTA and STTA for DME treatment after CS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000489716 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secondary Macular Hole Closure With Sub-Tenon Triamcinolone Acetonide.
J Vitreoretin Dis
August 2025
Department of Ophthalmology and Visual Sciences, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA, USA.
To evaluate the efficacy and safety of sub-Tenon triamcinolone acetonide in the management of secondary full-thickness macular holes after vitreoretinal surgeries or traumatic injury. This case series includes 3 patients with secondary macular holes. All patients were treated with 40 mg sub-Tenon triamcinolone acetonide injections for macular holes.
View Article and Find Full Text PDFEffectiveness and Safety of Intravitreal Brolucizumab for Diabetic Macular Edema After Vitrectomy: A Before-and-After Study at a Specialized Center in Japan.
Clin Ophthalmol
June 2025
Department of Ophthalmology, Gunma University Graduate School of Medicine, Gunma, 371-8511, Japan.
Purpose: To evaluate the efficacy and safety of intravitreal brolucizumab (IVBr), a vascular endothelial growth factor inhibitor, for injections in vitrectomized eyes with diabetic macular edema (DME) over 1 year.
Patients And Methods: This retrospective before-and-after study analyzed 23 eyes of 20 patients with DME after vitrectomy. Outcomes assessed over 1 year included best-corrected visual acuity (BCVA), central subfield retinal thickness (CST), and the number of IVBr injections administered.
Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema.
Jpn J Ophthalmol
September 2025
Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Purpose: This study aimed to assess the real-world outcomes, including intraocular inflammation (IOI), following administration of intravitreal brolucizumab (Beovu 6.0 mg/0.05 mL; Novartis) injections (IVBr) for diabetic macular edema (DME).
View Article and Find Full Text PDFIncidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review.
Diagnostics (Basel)
March 2025
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, CH-3010 Bern, Switzerland.
Cystoid macular edema (CMO) is a common complication that follows cataract surgery, presenting management challenges due to the lack of standardized treatment guidelines and the potential for spontaneous resolution. This study aimed to evaluate various treatment modalities for post-operative CMO, including topical non-steroidal anti-inflammatory drugs (NSAIDs), periocular steroids, and intravitreal injections. A systematic review of the literature was conducted to assess the efficacy of different treatment approaches for post-operative CMO.
View Article and Find Full Text PDFGraft-repositioning technique using infusion and small bubbles during Descemet's membrane endothelial keratoplasty.
BMC Ophthalmol
January 2025
Department of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Itabashi, Tokyo, Japan.
Background: Descemet's membrane endothelial keratoplasty (DMEK) is a highly effective procedure for corneal endothelial dysfunction; however, once a DMEK graft is deployed, repositioning can be challenging. Therefore, this study aimed to evaluate the efficacy of a technique that utilizes infusion and small air bubbles to reposition a misaligned deployed graft.
Methods: This retrospective interventional case series enrolled patients who underwent DMEK between January 2022 and July 2023, including cases where the DMEK graft was attached and unfolded in off-center positions".